The online version of this article (doi:10.1007/s00125-009-1453-1) contains supplementary material, which is available to authorised users.
The SDRN Epidemiology Group members involved in this study were (in alphabetical order): S. Brearley, University of Dundee; J. Chalmers, NHS Fife; H. M. Colhoun, University of Dundee & NHS Fife; S. Cunningham, University of Dundee; A. Emslie-Smith, GP & University of Dundee; C. Fischbacher, ISD Scotland; R. Lindsay, University of Glasgow; S. Livingstone, University of Dundee; R. McAlpine, University of Dundee; J. McKnight, University of Edinburgh & NHS Lothian; A. Morris, University of Dundee; D. Pearson, University of Aberdeen; J. Petrie, University of Dundee; S. Wild, University of Edinburgh
An erratum to this article can be found at http://dx.doi.org/10.1007/s00125-009-1503-8
The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin.
We used a nationwide diabetes clinical database that covers the majority of the Scottish population with diagnosed diabetes, and examined patients with diabetes who were exposed to any insulin therapy between 1 January 2002 and 31 December 2005. Among these we defined a fixed cohort based on exposure during a 4 month period in 2003 (n = 36,254, in whom 715 cases of cancer occurred) and a cohort of new insulin users across the period (n = 12,852 in whom 381 cancers occurred). Records from these cohorts were linked to cancer registry data up to the end of 2005. We used Cox proportional hazards models for survival analyses.
Those receiving any insulin glargine (n = 3,959) had the same incidence rate for all cancers as those not receiving insulin glargine (HR 1.02, 95% CI 0.77–1.36, p = 0.9 in the fixed cohort) The subset of patients using insulin glargine alone (n = 447) had a significantly higher incidence of all cancers than those using other insulins only (n = 32,295) (HR 1.55, 95% CI 1.01–2.37, p = 0.045), and those using insulin glargine with other insulins (n = 3,512) had a slightly lower incidence (HR 0.81, 95% CI 0.55–1.18, p = 0.26). There were important differences in baseline characteristics between these three groups, although the risk ratios were broadly unaltered on adjustment for these. Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79–2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46–7.85, p = 0.004). Among type 2 diabetic incident insulin users, no significant difference between the three groups was observed with respect to all cancer or breast cancer. All the above HRs are adjusted for age, calendar time prior cancer and type of diabetes, as appropriate, and are stratified according to sex.
Overall, insulin glargine use was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4 year time frame. Given the overall data, we consider the excess of cases of all cancers and breast cancer in the subgroup of insulin glargine only users to more likely reflect allocation bias rather than an effect of insulin glargine itself.
sanofi-aventis (2007) LANTUS (insulin glargine [rDNA origin] injection). Available from http://products.sanofi-aventis.us/lantus/lantus.pdf, accessed 15 May 2009
Lawson DH (2002). Insulin glargine (Lantus): Summary of recommendation. Available from www.scottishmedicines.org.uk/smc/files/Insuline%20Glargine%20FINAL.pdf, accessed 15 May 2009
National Institute for Clinical Excellence (2002) Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. Available from www.nice.org.uk/nicemedia/pdf/53_Insulin_analogues_full_guidance.pdf, accessed 15 May 2009
National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Available from www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf, accessed 15 May 2009
National Institute for Health and Clinical Excellence (2009) NICE implementation uptake report: insulin glargine for diabetes (types 1 and 2). Available from www.nice.org.uk/media/7B3/7C/IMPUptakeReportTA53CG66GlarginevFinal.pdf, accessed 15 May 2009
Horvath K, Jeitler K, Berghold A, et al. (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD005613
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397 PubMed
Scottish Index of Multiple Deprivation. Available from www.scotland.gov.uk/Topics/Statistics/SIMD/, accessed 20 May 2009
Malignant neoplasms of breast. Available from www.isdscotland.org/isd/5114.html, accessed 20 May 2009
The Scottish Record Linkage System. Available from http://www.isdscotland.org/isd/files/The%20Scottish%20Record%20Linkage%20System.doc, accessed 23 May 2009
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
H. M. Colhoun
SDRN Epidemiology Group
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II